시장보고서
상품코드
1443314

의약품 RA(Regulatory Affairs) 시장 : 성장, 향후 전망, 경쟁 분석(2023-2031년)

Pharmaceutical Regulatory Affairs Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

발행일: | 리서치사: Acute Market Reports | 페이지 정보: 영문 111 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

의약품 RA(Regulatory Affairs) 시장은 2024-2032년 예측 기간 동안 7.5%의 CAGR로 성장할 것으로 예상됩니다. 시장 촉진요인으로는 제약 컨설팅 서비스에 대한 수요 증가, 제품 등록 및 임상시험 신청에 대한 요구 사항의 확대, 법적 대리 업무의 중요성 증가 등이 시장을 형성하는 변혁적 힘을 강조하고 있습니다. 약사법 관련 문서 작성 및 출판의 장애요인은 약사법 관련 문서 작성과 관련된 복잡성을 의미합니다. 시장 세분화는 제약 컨설팅 서비스, 제품 등록 및 임상시험 신청의 중요성을 드러내며 제약 산업의 다양한 요구에 대한 미묘한 인사이트를 제공합니다. 지리적 동향은 북미의 우위를 강조하고, 경쟁 동향은 전략적 파트너십, 기술 투자, 경쟁력 유지를 위한 서비스 다각화의 중요성을 강조하고 있습니다.

약사 컨설팅 서비스에 대한 수요 증가

제약 산업의 제약 컨설팅 서비스에 대한 수요는 규제 프레임워크의 복잡성과 규정 준수에 대한 요구로 인해 상당한 성장을 보이고 있습니다. 업계 보고서와 시장 분석에 따르면, 컨설팅 서비스에 대한 수요가 지속적으로 증가하고 있으며, 이는 제약 산업이 규제 요건을 극복하기 위해 전문가 지도에 의존하고 있으며, 2024년부터 2032년까지 예측 기간 동안 이 분야에서 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다. 이는 규제 컨설팅 서비스가 진화하는 규제 표준을 준수하는 데 있어 매우 중요한 역할을 하고 있음을 강조합니다.

제품 등록 및 임상시험 신청 요건 확대

제약 업계는 제품 등록 및 임상시험 신청에 대한 요구사항이 확대되고 있습니다. 규제 당국의 최신 정보 및 업계 동향은 제품 승인 및 임상시험에 필요한 정밀 조사 및 문서화가 증가하고 있음을 입증하고 있습니다. 제품 등록 및 임상시험 신청과 관련된 복잡한 프로세스를 관리하기 위한 전문 서비스의 필요성에 대한 업계의 인식을 반영하여 2024년부터 2032년까지 예측 기간 동안 이 분야에서 가장 높은 CAGR을 기록할 것으로 예상됩니다.

RA(Regulatory Affairs) 업무에서 법정 대리 업무의 중요성 증대

기업들이 복잡한 규제 환경을 헤쳐나가는 데 있어 법률 전문 지식의 가치를 인식함에 따라 제약 및 의약품 분야에서 법률 대리 서비스가 주목받고 있습니다. 법적 절차, 업계 간행물, 기업 전략 등을 통해 규제 문제를 해결하기 위한 법적 대리인의 중요성이 증가하고 있음을 알 수 있으며, 2024년부터 2032년까지 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상되며, 이는 제약 업계가 법적 지원이 규제 준수에 있어 중요한 요소로 인식하고 있음을 보여줍니다.

약사법 관련 문서 작성 및 출판의 과제

RA(Regulatory Affairs) 업무의 전반적인 성장에도 불구하고, 약사법 관련 문서 작성 및 출판에 대한 도전이 두드러진 억제요인으로 부상하고 있습니다. 업계 인사이트와 전문가 분석에 따르면, 규제 문서의 복잡한 특성으로 인해 기업과 서비스 제공업체가 어려움을 겪고 있으며, 2024년부터 2032년까지 예측 기간 동안 이 분야에서 가장 높은 CAGR을 기록할 것으로 예상되며, 제약 관련 문서 작성 및 출판의 복잡성을 해결하기 위한 혁신적인 솔루션의 필요성이 강조되고 있습니다. 업계가 이러한 과제를 극복하는 과정에서 전반적인 RA(Regulatory Affairs)에 미치는 영향은 여전히 시장 관계자들에게 중요한 고려 사항입니다.

서비스별 시장 분석 : 약사 컨설팅 서비스가 시장을 독점

2023년 의약품 RA(Regulatory Affairs) 시장은 제약 컨설팅 서비스에서 큰 수익을 창출하고 있으며, 이 분야가 매출과 CAGR 모두에서 선두를 달리고 있습니다. 2024년부터 2032년까지 예측 기간 동안 가장 높은 CAGR을 기록한 분야는 제품 등록 및 임상시험 신청 분야로, 규제 프로세스 관리에 대한 전문적 서비스에 대한 수요가 증가하고 있음을 반영합니다.

적응증별 시장 분석 : 암 분야가 시장을 독점

2023년 의약품 RA(Regulatory Affairs) 시장은 암 적응증에서 큰 수익을 창출했으며, 이 카테고리가 매출과 CAGR 모두에서 1위를 차지했습니다. 2024년부터 2032년까지 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상되는 적응증은 신경계 적응증으로, 이는 신경계 전문 의약품에 대한 규제 요구사항이 증가할 것으로 예상된다는 것을 보여줍니다.

북미는 여전히 세계 리더

지역별로 보면 2023년 의약품 RA(Regulatory Affairs) 시장은 역동적인 추세를 보이며 북미가 매출과 CAGR 모두에서 1위를 차지했습니다. 이는 이 지역의 탄탄한 제약 산업과 진화하는 규제 상황을 반영합니다. 유럽과 아시아태평양도 매출에 크게 기여하여 규제 요건과 제약 서비스에 대한 수요 증가라는 세계 추세를 보여주었습니다. 이 지리적 구분은 시장 세분화 시장을 형성하는 지역적 역학에 대한 인사이트를 제공합니다.

시장 점유율 확대를 위한 전략적 파트너십과 협업

의약품 RA(Regulatory Affairs) 시장의 경쟁 환경은 시장 지위를 강화하기 위한 전략을 채택하는 주요 기업들에 의해 특징지어집니다. QuintilesIMS, Parexel International Corporation, ICON plc, Freyr, IQVIA Inc, WuXi AppTec Charles River Laboratories, Labcorp Drug Development, Pharmalex GmbH, Pharmexon, Genpact와 같은 주요 기업들은 시장 기회를 활용하기 위해 다양한 전략을 실행하고 있습니다. 의약품 RA(Regulatory Affairs) 시장의 주요 업체들은 전략적 파트너십과 협업을 주요 전략으로 삼고 있습니다. 파트너십 발표와 공동 이니셔티브의 과제는 QuintilesIMS와 같은 기업들이 규제 과제를 극복하기 위해 전문 지식을 결합하고 있음을 보여 줍니다. 2023년 이들 기업은 상당한 수익을 기록했으며, 2024년부터 2032년까지 예측 기간 동안 증가세를 보일 것으로 예상됩니다. 업계는 협력적 접근 방식을 통해 진화하는 규제 요건에 대응하고 고객에게 종합적인 솔루션을 제공하는 데 있어 최전선에 서고 있습니다. 기술 솔루션에 대한 투자는 의약품 RA(Regulatory Affairs) 시장의 주요 기업들 사이에서 두드러진 추세입니다. 기술 인수와 디지털 혁신에 대한 노력은 규제 프로세스를 간소화하는 데 있어 기술의 역할에 대한 업계의 인식을 뒷받침하고 있습니다. 2023년에는 ICON plc와 같은 기업이 기술 발전에 많은 투자를 하고 있으며, 이는 규제 업무에서 디지털 솔루션의 세계적 확산과 일치합니다. 시장이 혁신을 받아들이는 가운데, 디지털 혁신을 우선시하는 기업은 경쟁력을 유지하고 고객에게 효율적이고 규정을 준수하는 솔루션을 제공할 수 있을 것으로 예상됩니다.

본 보고서에서 답변하는 주요 질문

의약품 RA(Regulatory Affairs) 시장의 성장에 영향을 미치는 주요 미시적 및 거시적 환경 요인은 무엇인가?

현재 및 예측 기간 동안 제품 부문 및 지역에 대한 주요 투자 포켓은 무엇인가?

2031년까지의 추정치 및 시장 전망

예측 기간 동안 가장 빠른 CAGR을 기록한 부문은?

시장 점유율이 높은 부문과 그 이유는?

중저소득 국가는 의약품 RA(Regulatory Affairs) 시장에 투자하고 있는가?

의약품 RA(Regulatory Affairs) 시장에서 가장 큰 지역 시장은 어디인가?

아시아태평양, 라틴아메리카, 중동 및 아프리카 등 신흥 시장의 시장 동향과 역학은?

의약품 RA(Regulatory Affairs) 시장의 성장을 촉진하는 주요 동향은?

세계 의약품 RA(Regulatory Affairs) 시장에서 존재감을 높이기 위한 주요 경쟁사 및 주요 전략은?

목차

제1장 서문

  • 보고서 내용
    • 보고서 목적
    • 대상자
    • 주요 제공
  • 시장 세분화
  • 조사 방법
    • 단계 I - 2차 조사
    • 단계 II - 1차 조사
    • 단계 III - 전문가 패널 리뷰
    • 가정
    • 채용한 접근법

제2장 주요 요약

제3장 의약품 RA(Regulatory Affairs) 시장 : 경쟁 분석

  • 주요 벤더의 시장에서의 포지셔닝
  • 벤더가 채용하는 전략
  • 주요 산업 전략
  • 계층 분석 : 2023 vs 2032

제4장 의약품 RA(Regulatory Affairs) 시장 : 거시적 분석과 시장 역학

  • 서론
  • 세계의 의약품 RA(Regulatory Affairs) 시장 금액 2022-2032
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 주요 과제
    • 주요 기회
  • 성장 촉진요인과 억제요인의 영향 분석
  • See-Saw 분석
  • Porter's Five Forces 모델
    • 구매자의 교섭력
    • 구매자의 교섭력
    • 대체품의 위협
    • 신규 참여업체의 위협
    • 경쟁 기업 간의 경쟁 관계
  • PESTEL 분석
    • 정치적 상황
    • 경제 상황
    • 테크놀러지 상황
    • 법적 상황
    • 사회적 상황

제5장 의약품 RA(Regulatory Affairs) 시장 : 서비스별 2022-2032

  • 시장 개요
  • 성장·매출 분석 : 2023 vs 2032
  • 시장 세분화
    • 규제 컨설팅
    • 법정 대리인
    • 규제에 관한 집필과 출판
      • 집필
      • 출판
    • 제품 등록과 임상시험 신청
    • 기타 서비스

제6장 의약품 RA(Regulatory Affairs) 시장 : 카테고리별 2022-2032

  • 시장 개요
  • 성장·매출 분석 : 2023 vs 2032
  • 시장 세분화
    • 약물
      • 이노베이터
      • 제네릭
    • 생물학적 제제
      • 바이오테크놀러지
      • ATMP
      • 바이오시밀러

제7장 의약품 RA(Regulatory Affairs) 시장 : 적응증별 2022-2032

  • 시장 개요
  • 성장·매출 분석 : 2023 vs 2032
  • 시장 세분화
    • 종양학
    • 신경내과
    • 심장병학
    • 면역학
    • 기타

제8장 의약품 RA(Regulatory Affairs) 시장 : 제품 단계별 2022-2032

  • 시장 개요
  • 성장·매출 분석 : 2023 vs 2032
  • 시장 세분화
    • 전임상
    • 임상 연구
    • PMA

제9장 의약품 RA(Regulatory Affairs) 시장 : 서비스 프로바이더별 2022-2032

  • 시장 개요
  • 성장·매출 분석 : 2023 vs 2032
  • 시장 세분화
    • 사내
    • 아웃소싱

제10장 의약품 RA(Regulatory Affairs) 시장 : 기업 규모별 2022-2032

  • 시장 개요
  • 성장·매출 분석 : 2023 vs 2032
  • 시장 세분화

제11장 북미의 의약품 RA(Regulatory Affairs) 시장 2022-2032

  • 시장 개요
  • 의약품 RA(Regulatory Affairs) 시장 : 서비스별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 카테고리별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 적응증별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 제품 단계별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 서비스 프로바이더별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 기업 규모별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 지역별 2022-2032
    • 북미
      • 미국
      • 캐나다
      • 기타 북미

제12장 영국과 유럽연합의 의약품 RA(Regulatory Affairs) 시장 2022-2032

  • 시장 개요
  • 의약품 RA(Regulatory Affairs) 시장 : 서비스별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 카테고리별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 적응증별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 제품 단계별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 서비스 프로바이더별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 기업 규모별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 지역별 2022-2032
    • 영국과 유럽연합
      • 영국
      • 독일
      • 스페인
      • 이탈리아
      • 프랑스
      • 기타 유럽

제13장 아시아태평양의 의약품 RA(Regulatory Affairs) 시장 2022-2032

  • 시장 개요
  • 의약품 RA(Regulatory Affairs) 시장 : 서비스별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 카테고리별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 적응증별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 제품 단계별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 서비스 프로바이더별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 기업 규모별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 지역별 2022-2032
    • 아시아태평양
      • 중국
      • 일본
      • 인도
      • 호주
      • 한국
      • 기타 아시아태평양

제14장 라틴아메리카의 의약품 RA(Regulatory Affairs) 시장 2022-2032

  • 시장 개요
  • 의약품 RA(Regulatory Affairs) 시장 : 서비스별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 카테고리별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 적응증별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 제품 단계별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 서비스 프로바이더별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 기업 규모별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 지역별 2022-2032
    • 라틴아메리카
      • 브라질
      • 멕시코
      • 기타 라틴아메리카

제15장 중동 및 아프리카의 의약품 RA(Regulatory Affairs) 시장 2022-2032

  • 시장 개요
  • 의약품 RA(Regulatory Affairs) 시장 : 서비스별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 카테고리별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 적응증별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 제품 단계별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 서비스 프로바이더별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 기업 규모별 2022-2032
  • 의약품 RA(Regulatory Affairs) 시장 : 지역별 2022-2032
    • 중동 및 아프리카
      • GCC
      • 아프리카
      • 기타 중동 및 아프리카

제16장 기업 개요

  • QuintilesIMS
  • Parexel International Corporation
  • ICON plc
  • Freyr
  • IQVIA Inc
  • WuXi AppTec
  • Charles River Laboratories
  • Labcorp Drug Development
  • Pharmalex GmbH
  • Pharmexon
  • Genpact
  • 기타 주요 기업
ksm 24.03.14

The pharmaceutical regulatory affairs market is expected to grow at a CAGR of 7.5% during the forecast period of 2024 to 2032. The identified drivers, including increasing demand for regulatory consulting services, expanding requirements for product registration and clinical trial applications, and the rising importance of legal representation, underscore the transformative forces shaping the market. The restraint related to challenges in regulatory writing and publishing signifies the complexities associated with documentation in regulatory affairs. Market segmentation reveals the significance of regulatory consulting services and product registration and clinical trial applications, providing nuanced insights into the diverse needs of the pharmaceutical industry. Geographic trends highlight the dominance of North America, while competitive trends underscore the importance of strategic partnerships, technological investments, and service diversification in maintaining a competitive edge.

Increasing Demand for Regulatory Consulting Services

The demand for regulatory consulting services in the pharmaceutical industry has witnessed substantial growth, driven by the complexities of regulatory frameworks and the need for compliance. Industry reports and market analyses provide evidence of a consistent rise in the demand for consulting services, indicating the pharmaceutical sector's reliance on expert guidance to navigate regulatory requirements. The highest Compound Annual Growth Rate (CAGR) during the forecast period from 2024 to 2032 is anticipated in this segment, highlighting the crucial role of regulatory consulting services in ensuring adherence to evolving regulatory standards.

Expanding Requirements for Product Registration & Clinical Trial Applications

The pharmaceutical landscape has witnessed an expansion in the requirements for product registration and clinical trial applications. Evidences from regulatory updates and industry trends underscore the increasing scrutiny and documentation needed for product approvals and clinical trials. The highest CAGR during the forecast period from 2024 to 2032 is expected in this segment, reflecting the industry's recognition of the need for specialized services to manage the intricate processes associated with product registration and clinical trial applications.

Rising Importance of Legal Representation in Regulatory Affairs

Legal representation has gained prominence in pharmaceutical regulatory affairs, with companies recognizing the value of legal expertise in navigating complex regulatory landscapes. Evidences from legal proceedings, industry publications, and corporate strategies highlight the escalating importance of legal representation in addressing regulatory challenges. The highest CAGR during the forecast period from 2024 to 2032 is anticipated in this segment, signaling the pharmaceutical industry's acknowledgment of legal support as a critical element in regulatory compliance.

Challenges in Regulatory Writing & Publishing

Despite the overall growth in regulatory affairs services, challenges in regulatory writing and publishing have emerged as a notable restraint. Evidences from industry insights and expert analyses indicate that the intricate nature of regulatory documentation poses challenges for companies and service providers. The highest CAGR during the forecast period from 2024 to 2032 is expected in this segment, underscoring the need for innovative solutions to address the complexities associated with regulatory writing and publishing. As the industry navigates these challenges, the impact on the overall regulatory affairs landscape remains a key consideration for market players.

Market Analysis by Services: Regulatory Consulting Services Dominate the Market

In 2023, the pharmaceutical regulatory affairs market demonstrated substantial revenue from regulatory consulting services, with this segment leading in both revenue and CAGR. This reflects the industry's reliance on expert guidance to ensure compliance with evolving regulatory standards. The highest CAGR during the forecast period from 2024 to 2032 is expected in the category of product registration and clinical trial applications, showcasing the increasing demand for specialized services in managing regulatory processes.

Market Analysis by Indication: OncologySegment Dominates the Market

In 2023, the pharmaceutical regulatory affairs market witnessed significant revenue from the oncology indication, with this category leading in both revenue and CAGR. This highlights the regulatory complexities associated with oncology products and the need for specialized regulatory services in this therapeutic area. The highest CAGR during the forecast period from 2024 to 2032 is expected in the neurology indication category, signaling the anticipated growth in regulatory requirements for neurology-focused pharmaceuticals.

North America remains the Global Leader

Geographically, the pharmaceutical regulatory affairs market exhibited dynamic trends in 2023, with North America leading in both revenue generation and the highest CAGR. This reflects the region's robust pharmaceutical industry and the evolving regulatory landscape. Europe and Asia-Pacific also contributed significantly to revenue, showcasing a global trend towards increased regulatory requirements and the demand for regulatory affairs services. This geographic segmentation provides insights into the regional dynamics shaping the pharmaceutical regulatory affairs market.

Strategic Partnerships and Collaborations to Enhance Market Share

The pharmaceutical regulatory affairs market's competitive landscape is marked by key players adopting strategies to enhance their market position. Major companies, including QuintilesIMS, Parexel International Corporation, ICON plc, Freyr, IQVIA Inc, WuXi AppTec, Charles River Laboratories, Labcorp Drug Development, Pharmalex GmbH, Pharmexon, and Genpact, have implemented diverse strategies to capitalize on market opportunities. Leading players in the pharmaceutical regulatory affairs market prioritize strategic partnerships and collaborations as key strategies. Evidences from partnership announcements and collaborative initiatives highlight the efforts of companies like QuintilesIMS to leverage combined expertise in navigating regulatory challenges. In 2023, these companies reported substantial revenues, with a projected increase during the forecast period from 2024 to 2032. The industry's commitment to collaborative approaches positions it at the forefront of addressing evolving regulatory requirements and offering comprehensive solutions to clients. Investment in technological solutions is a notable trend among top players in the pharmaceutical regulatory affairs market. Evidences from technology acquisitions and digital transformation initiatives underscore the industry's recognition of the role of technology in streamlining regulatory processes. In 2023, companies like ICON plc demonstrated significant investments in technological advancements, aligning with the global push for digital solutions in regulatory affairs. As the market embraces technological innovation, companies that prioritize digital transformation are expected to maintain a competitive edge, offering efficient and compliant solutions to clients.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofPharmaceutical Regulatory Affairs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Pharmaceutical Regulatory Affairs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Services

    • Regulatory Consulting
    • Legal Representation
    • Regulatory Writing & Publishing
  • Writing
  • Publishing
    • Product Registration & Clinical Trial Applications
    • Other Services

Category

    • Drugs
  • Innovator

4 Preclinical

4 Clinical

4 Pre-Market Approval (PMA)

  • Generics

4 Preclinical

4 Clinical

4 Pre-Market Approval (PMA)

    • Biologics
  • Biotech

4 Preclinical

4 Clinical

4 Pre-Market Approval (PMA)

  • ATMP

4 Preclinical

4 Clinical

4 Pre-Market Approval (PMA)

  • Biosimilars

4 Preclinical

4 Clinical

4 Pre-Market Approval (PMA)

Indication

    • Oncology
    • Neurology
    • Cardiology
    • Immunology
    • Others

Product Stage

    • Preclinical
    • Clinical studies
    • PMA

Service Provider

    • In-house
    • Outsourcing

Company Size

    • Small
    • Medium
    • Large

Region Segment (2021-2031; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Pharmaceutical Regulatory Affairs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Pharmaceutical Regulatory Affairs market?

Which is the largest regional market for Pharmaceutical Regulatory Affairs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Pharmaceutical Regulatory Affairs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Pharmaceutical Regulatory Affairs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Pharmaceutical Regulatory Affairs Market
  • 2.2. Global Pharmaceutical Regulatory Affairs Market, By Services, 2023 (US$ Million)
  • 2.3. Global Pharmaceutical Regulatory Affairs Market, By Category, 2023 (US$ Million)
  • 2.4. Global Pharmaceutical Regulatory Affairs Market, By Indication, 2023 (US$ Million)
  • 2.5. Global Pharmaceutical Regulatory Affairs Market, By Product Stage, 2023 (US$ Million)
  • 2.6. Global Pharmaceutical Regulatory Affairs Market, By Service Provider, 2023 (US$ Million)
  • 2.7. Global Pharmaceutical Regulatory Affairs Market, By Company Size, 2023 (US$ Million)
  • 2.8. Global Pharmaceutical Regulatory Affairs Market, By Geography, 2023 (US$ Million)
  • 2.9. Attractive Investment Proposition by Geography, 2023

3. Pharmaceutical Regulatory Affairs Market: Competitive Analysis

  • 3.1. Market Positioning of Key Pharmaceutical Regulatory Affairs Market Vendors
  • 3.2. Strategies Adopted by Pharmaceutical Regulatory Affairs Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2023 Versus 2032

4. Pharmaceutical Regulatory Affairs Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Pharmaceutical Regulatory Affairs Market Value, 2022 - 2032, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 5.3. Market Segmentation
    • 5.3.1. Regulatory Consulting
    • 5.3.2. Legal Representation
    • 5.3.3. Regulatory Writing & Publishing
      • 5.3.3.1. Writing
      • 5.3.3.2. Publishing
    • 5.3.4. Product Registration & Clinical Trial Applications
    • 5.3.5. Other Services

6. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 6.3. Market Segmentation
    • 6.3.1. Drugs
      • 6.3.1.1. Innovator
        • 6.3.1.1.1. Preclinical
        • 6.3.1.1.2. Clinical
        • 6.3.1.1.3. Pre-Market Approval (PMA)
      • 6.3.1.2. Generics
        • 6.3.1.2.1. Preclinical
        • 6.3.1.2.2. Clinical
        • 6.3.1.2.3. Pre-Market Approval (PMA)
    • 6.3.2. Biologics
      • 6.3.2.1. Biotech
        • 6.3.2.1.1. Preclinical
        • 6.3.2.1.2. Clinical
        • 6.3.2.1.3. Pre-Market Approval (PMA)
      • 6.3.2.2. ATMP
        • 6.3.2.2.1. Preclinical
        • 6.3.2.2.2. Clinical
        • 6.3.2.2.3. Pre-Market Approval (PMA)
      • 6.3.2.3. Biosimilars
        • 6.3.2.3.1. Preclinical
        • 6.3.2.3.2. Clinical
        • 6.3.2.3.3. Pre-Market Approval (PMA)

7. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 7.3. Market Segmentation
    • 7.3.1. Oncology
    • 7.3.2. Neurology
    • 7.3.3. Cardiology
    • 7.3.4. Immunology
    • 7.3.5. Others

8. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 8.3. Market Segmentation
    • 8.3.1. Preclinical
    • 8.3.2. Clinical studies
    • 8.3.3. PMA

9. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 9.3. Market Segmentation
    • 9.3.1. In-house
    • 9.3.2. Outsourcing

10. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 10.3. Market Segmentation
    • 10.3.1. Small
    • 10.3.2. Medium
    • 10.3.3. Large

11. North America Pharmaceutical Regulatory Affairs Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
  • 11.3. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
  • 11.4. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
  • 11.5. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
  • 11.6. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
  • 11.7. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
  • 11.8.Pharmaceutical Regulatory Affairs Market: By Region, 2022-2032, USD (Million)
    • 11.8.1.North America
      • 11.8.1.1. U.S.
        • 11.8.1.1.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 11.8.1.1.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 11.8.1.1.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 11.8.1.1.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 11.8.1.1.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 11.8.1.1.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 11.8.1.2. Canada
        • 11.8.1.2.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 11.8.1.2.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 11.8.1.2.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 11.8.1.2.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 11.8.1.2.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 11.8.1.2.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 11.8.1.3. Rest of North America
        • 11.8.1.3.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 11.8.1.3.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 11.8.1.3.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 11.8.1.3.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 11.8.1.3.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 11.8.1.3.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)

12. UK and European Union Pharmaceutical Regulatory Affairs Market, 2022-2032, USD (Million)

  • 12.1. Market Overview
  • 12.2. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
  • 12.3. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
  • 12.4. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
  • 12.5. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
  • 12.6. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
  • 12.7. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
  • 12.8.Pharmaceutical Regulatory Affairs Market: By Region, 2022-2032, USD (Million)
    • 12.8.1.UK and European Union
      • 12.8.1.1. UK
        • 12.8.1.1.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 12.8.1.1.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 12.8.1.1.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 12.8.1.1.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 12.8.1.1.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 12.8.1.1.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 12.8.1.2. Germany
        • 12.8.1.2.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 12.8.1.2.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 12.8.1.2.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 12.8.1.2.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 12.8.1.2.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 12.8.1.2.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 12.8.1.3. Spain
        • 12.8.1.3.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 12.8.1.3.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 12.8.1.3.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 12.8.1.3.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 12.8.1.3.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 12.8.1.3.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 12.8.1.4. Italy
        • 12.8.1.4.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 12.8.1.4.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 12.8.1.4.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 12.8.1.4.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 12.8.1.4.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 12.8.1.4.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 12.8.1.5. France
        • 12.8.1.5.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 12.8.1.5.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 12.8.1.5.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 12.8.1.5.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 12.8.1.5.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 12.8.1.5.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 12.8.1.6. Rest of Europe
        • 12.8.1.6.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 12.8.1.6.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 12.8.1.6.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 12.8.1.6.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 12.8.1.6.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 12.8.1.6.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)

13. Asia Pacific Pharmaceutical Regulatory Affairs Market, 2022-2032, USD (Million)

  • 13.1. Market Overview
  • 13.2. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
  • 13.3. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
  • 13.4. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
  • 13.5. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
  • 13.6. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
  • 13.7. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
  • 13.8.Pharmaceutical Regulatory Affairs Market: By Region, 2022-2032, USD (Million)
    • 13.8.1.Asia Pacific
      • 13.8.1.1. China
        • 13.8.1.1.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 13.8.1.1.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 13.8.1.1.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 13.8.1.1.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 13.8.1.1.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 13.8.1.1.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 13.8.1.2. Japan
        • 13.8.1.2.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 13.8.1.2.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 13.8.1.2.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 13.8.1.2.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 13.8.1.2.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 13.8.1.2.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 13.8.1.3. India
        • 13.8.1.3.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 13.8.1.3.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 13.8.1.3.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 13.8.1.3.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 13.8.1.3.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 13.8.1.3.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 13.8.1.4. Australia
        • 13.8.1.4.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 13.8.1.4.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 13.8.1.4.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 13.8.1.4.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 13.8.1.4.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 13.8.1.4.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 13.8.1.5. South Korea
        • 13.8.1.5.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 13.8.1.5.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 13.8.1.5.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 13.8.1.5.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 13.8.1.5.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 13.8.1.5.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 13.8.1.6. Rest of Asia Pacific
        • 13.8.1.6.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 13.8.1.6.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 13.8.1.6.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 13.8.1.6.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 13.8.1.6.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 13.8.1.6.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)

14. Latin America Pharmaceutical Regulatory Affairs Market, 2022-2032, USD (Million)

  • 14.1. Market Overview
  • 14.2. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
  • 14.3. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
  • 14.4. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
  • 14.5. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
  • 14.6. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
  • 14.7. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
  • 14.8.Pharmaceutical Regulatory Affairs Market: By Region, 2022-2032, USD (Million)
    • 14.8.1.Latin America
      • 14.8.1.1. Brazil
        • 14.8.1.1.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 14.8.1.1.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 14.8.1.1.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 14.8.1.1.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 14.8.1.1.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 14.8.1.1.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 14.8.1.2. Mexico
        • 14.8.1.2.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 14.8.1.2.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 14.8.1.2.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 14.8.1.2.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 14.8.1.2.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 14.8.1.2.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 14.8.1.3. Rest of Latin America
        • 14.8.1.3.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 14.8.1.3.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 14.8.1.3.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 14.8.1.3.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 14.8.1.3.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 14.8.1.3.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)

15. Middle East and Africa Pharmaceutical Regulatory Affairs Market, 2022-2032, USD (Million)

  • 15.1. Market Overview
  • 15.2. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
  • 15.3. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
  • 15.4. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
  • 15.5. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
  • 15.6. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
  • 15.7. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
  • 15.8.Pharmaceutical Regulatory Affairs Market: By Region, 2022-2032, USD (Million)
    • 15.8.1.Middle East and Africa
      • 15.8.1.1. GCC
        • 15.8.1.1.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 15.8.1.1.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 15.8.1.1.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 15.8.1.1.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 15.8.1.1.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 15.8.1.1.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 15.8.1.2. Africa
        • 15.8.1.2.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 15.8.1.2.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 15.8.1.2.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 15.8.1.2.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 15.8.1.2.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 15.8.1.2.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)
      • 15.8.1.3. Rest of Middle East and Africa
        • 15.8.1.3.1. Pharmaceutical Regulatory Affairs Market: By Services, 2022-2032, USD (Million)
        • 15.8.1.3.2. Pharmaceutical Regulatory Affairs Market: By Category, 2022-2032, USD (Million)
        • 15.8.1.3.3. Pharmaceutical Regulatory Affairs Market: By Indication, 2022-2032, USD (Million)
        • 15.8.1.3.4. Pharmaceutical Regulatory Affairs Market: By Product Stage, 2022-2032, USD (Million)
        • 15.8.1.3.5. Pharmaceutical Regulatory Affairs Market: By Service Provider, 2022-2032, USD (Million)
        • 15.8.1.3.6. Pharmaceutical Regulatory Affairs Market: By Company Size, 2022-2032, USD (Million)

16. Company Profile

  • 16.1. QuintilesIMS
    • 16.1.1. Company Overview
    • 16.1.2. Financial Performance
    • 16.1.3. Product Portfolio
    • 16.1.4. Strategic Initiatives
  • 16.2. Parexel International Corporation
    • 16.2.1. Company Overview
    • 16.2.2. Financial Performance
    • 16.2.3. Product Portfolio
    • 16.2.4. Strategic Initiatives
  • 16.3. ICON plc
    • 16.3.1. Company Overview
    • 16.3.2. Financial Performance
    • 16.3.3. Product Portfolio
    • 16.3.4. Strategic Initiatives
  • 16.4. Freyr
    • 16.4.1. Company Overview
    • 16.4.2. Financial Performance
    • 16.4.3. Product Portfolio
    • 16.4.4. Strategic Initiatives
  • 16.5. IQVIA Inc
    • 16.5.1. Company Overview
    • 16.5.2. Financial Performance
    • 16.5.3. Product Portfolio
    • 16.5.4. Strategic Initiatives
  • 16.6. WuXi AppTec
    • 16.6.1. Company Overview
    • 16.6.2. Financial Performance
    • 16.6.3. Product Portfolio
    • 16.6.4. Strategic Initiatives
  • 16.7. Charles River Laboratories
    • 16.7.1. Company Overview
    • 16.7.2. Financial Performance
    • 16.7.3. Product Portfolio
    • 16.7.4. Strategic Initiatives
  • 16.8. Labcorp Drug Development
    • 16.8.1. Company Overview
    • 16.8.2. Financial Performance
    • 16.8.3. Product Portfolio
    • 16.8.4. Strategic Initiatives
  • 16.9. Pharmalex GmbH
    • 16.9.1. Company Overview
    • 16.9.2. Financial Performance
    • 16.9.3. Product Portfolio
    • 16.9.4. Strategic Initiatives
  • 16.10. Pharmexon
    • 16.10.1. Company Overview
    • 16.10.2. Financial Performance
    • 16.10.3. Product Portfolio
    • 16.10.4. Strategic Initiatives
  • 16.11. Genpact
    • 16.11.1. Company Overview
    • 16.11.2. Financial Performance
    • 16.11.3. Product Portfolio
    • 16.11.4. Strategic Initiatives
  • 16.12. Other Notable Players
    • 16.12.1. Company Overview
    • 16.12.2. Financial Performance
    • 16.12.3. Product Portfolio
    • 16.12.4. Strategic Initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제